摘要
目的通过研究活化增视颗粒对兔眼实验性增殖性玻璃体视网膜病变(PVR)玻璃体中MCP-1以及TGF-β2的影响,探讨活化增视颗粒对PVR的作用机制。方法将45只新西兰大白兔随机平均分为模型对照组、沃丽汀组、活化增视颗粒组,采用兔眼玻璃体内注射巨噬细胞的方法建立PVR的动物模型,各组于3、7、14、21、28 d分别随机处死3只,ELISA检测玻璃体液中MCP-1和TGF-β2的质量浓度。结果活化增视颗粒组在7 d时可显著降低兔玻璃体内MCP-1表达,与沃丽汀组及对照组相比差异有统计学意义(P<0.01),活化增视颗粒组在3 d时玻璃体内TGF-β2质量浓度开始升高,与对照组相比差异有统计学意义(P<0.01),与沃丽汀组相比差异无统计学意义(P>0.05),至14 d时达到高峰,与对照组及沃丽汀组相比差异有统计学意义(P<0.01)。结论活化增视颗粒主要在PVR炎症期及增生早期通过降低玻璃体中MCP-1和升高玻璃体中TGF-β2的质量浓度来抑制PVR的发生。
Objective To study the curative and preventive effects and the mechanism of huohuazengshi（HHZS） medicinalgranules on proliferative vitreoretinopathy（PVR） through establishing an experimental animal model of PVR.Methods 45 rabbits（45 eyes） were randomly divided into the model group,the joletion tablet group and the HHZS medicinalgranules group.Experimental PVR models were induced by injecting macrophages into the vitreous.Contents of MCP-1 and TGF-β2 in the vitreous humour were determined by ELISA.Then the rabbits were executed at days 3,7,14,21 and 28.Results Compared with the model group and the joletion tablet group,the content of MCP-1 in the HHZS medicinalgranules group was significantly decreased at day 7（P0.01）,while the content of TGF-β2 was increased at day 3 and reached the peak at day 14（P0.01）.Conclusion HHZS medicinalgranules could inhibit the formation and development of PVR by decreasing the content of MCP-1 and increasing the content of TGF-β2 in the vitreous at the inflammatory phase and early proliferative phase.
出处
《山东大学学报（医学版）》
CAS
北大核心
2011年第4期61-64,共4页
Journal of Shandong University:Health Sciences
基金
山东省自然科学基金资助项目(Y2007C129)
